Alvotech
http://www.alvotech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alvotech
Alvotech Makes Multiple Moves As It Allies With Advanz For Five European Biosimilars
In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.
Teva Is Committed To Alvotech Alliance – But Would ‘Love’ To Move On Adalimumab ‘Soon’
Teva has spoken of its US biosimilars alliance with Alvotech, in the wake of several major setbacks for the companies’ plans to launch a biosimilar to AbbVie’s Humira (adalimumab) juggernaut on 1 July.
Alvotech Links Up With Polifarma On Proposed Eylea Biosimilar
Alvotech has signed an agreement with Polifarma to distribute its proposed aflibercept biosimilar in Turkey. The compound, AVT06, is currently in the development stage.
Teva Expects To Carve Out Sizable Niche For Uzedy In Antipsychotic Market
Uzedy was recently approved by the US FDA as an extended-release subcutaneous formula of risperidone; it is poised to be a new prong in Teva’s branded portfolio.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Alvotech Iceland
- Alvotech Germany GmnH
- Alvotech Swiss AG
- Glycothera
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice